Chemical Compound Review:
Trivastal 2-[4-(benzo[1,3]dioxol-5...
Synonyms:
Trivastan, piribedil, Piribedile, Piribendyl, Piribedilum, ...
- Sleep attacks and Parkinson's disease treatment. Ferreira, J.J., Galitzky, M., Montastruc, J.L., Rascol, O. Lancet (2000)
- Piribedil: its synergistic effect in multidrug regimens for parkinsonism. Feigenson, J.S., Sweet, R.D., McDowell, F.H. Neurology (1976)
- Reversibility of hemodynamic hypofrontality in schizophrenia. Geraud, G., Arné-Bès, M.C., Güell, A., Bes, A. J. Cereb. Blood Flow Metab. (1987)
- Separation of peripheral dopamine receptors by a selective DA1 antagonist, SCH 23390. Goldberg, L.I., Glock, D., Kohli, J.D., Barnett, A. Hypertension (1984)
- EMG patterns in abnormal involuntary movements induced by neuroleptics. Bathien, N., Koutlidis, R.M., Rondot, P. J. Neurol. Neurosurg. Psychiatr. (1984)
- Blockage of narcotic-induced dopamine receptor supersensitivity by cyclo(Leu-Gly). Ritzmann, R.F., Walter, R., Bhargava, H.N., Flexner, L.B. Proc. Natl. Acad. Sci. U.S.A. (1979)
- Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Peretti, C.S., Gierski, F., Harrois, S. Psychopharmacology (Berl.) (2004)
- Piribedil for restless legs syndrome: a pilot study. Evidente, V.G. Mov. Disord. (2001)
- Apomorphine and piribedil in rats: biochemical and pharmacologic studies. Butterworth, R.F., Poignant, J.C., Barbeau, A. Advances in neurology. (1975)
- Chemically modified carbon paste electrode for the potentiometric flow injection analysis of piribedil in pharmaceutical preparation and urine. Ibrahim, H. Journal of pharmaceutical and biomedical analysis. (2005)
- Effects of a dopaminergic agonist (piribedil) on cerebral blood flow in man. Güell, A., Géraud, G., Jauzac, P., Victor, G., Arné-Bès, M.C. J. Cereb. Blood Flow Metab. (1982)
- Decline of tuberoinfundibular dopaminergic function resulting from chronic hyperprolactinemia in rats. Sarkar, D.K., Gottschall, P.E., Meites, J. Endocrinology (1984)
- Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. Gobert, A., Di Cara, B., Cistarelli, L., Millan, M.J. J. Pharmacol. Exp. Ther. (2003)
- The Dopamine Agonist Piribedil with L-DOPA Improves Attentional Dysfunction: Relevance for Parkinson's Disease. Turle-Lorenzo, N., Maurin, B., Puma, C., Chezaubernard, C., Morain, P., Baunez, C., Nieoullon, A., Amalric, M. J. Pharmacol. Exp. Ther. (2006)
- Parkinsonism by haloperidol and piribedil. Corsini, G.U., Del Zompo, M., Spissu, A., Mangoni, A., Gessa, G.L. Psychopharmacology (Berl.) (1978)
- Effects of apomorphine and piribedil on pentylenetetrazol-induced seizures in mice. Riffee, W.H., Wilcox, R.E., Goldman, C.P., Smith, R.V. Psychopharmacology (Berl.) (1981)
- Identification of amino Acid determinants of dopamine 2 receptor synthetic agonist function. Al-Fulaij, M.A., Ren, Y., Beinborn, M., Kopin, A.S. J. Pharmacol. Exp. Ther. (2007)
- The Parkinson-Control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Castro-Caldas, A., Delwaide, P., Jost, W., Merello, M., Williams, A., Lamberti, P., Aguilar, M., Del Signore, S., Cesaro, P. Mov. Disord. (2006)
- Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. Millan, M.J., Cussac, D., Milligan, G., Carr, C., Audinot, V., Gobert, A., Lejeune, F., Rivet, J.M., Brocco, M., Duqueyroix, D., Nicolas, J.P., Boutin, J.A., Newman-Tancredi, A. J. Pharmacol. Exp. Ther. (2001)
- Femoral vasodilatation produced by piribedil (ET495) and its metabolite S584 in the hindleg of the dog. Buylaert, W.A. Naunyn Schmiedebergs Arch. Pharmacol. (1977)
- Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Calzi, F., Bellasio, R., Guiso, G., Caccia, S., Tacconi, M.T. Eur. J. Pharmacol. (1997)
- In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Cagnotto, A., Parotti, L., Mennini, T. Eur. J. Pharmacol. (1996)
- Cerebral circulatory and metabolic effects of piribedil. McCulloch, J., Edvinsson, L. Eur. J. Pharmacol. (1980)
- Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. Gobert, A., Rivet, J.M., Audinot, V., Cistarelli, L., Spedding, M., Vian, J., Peglion, J.L., Millan, M.J. J. Pharmacol. Exp. Ther. (1995)
- Dopaminergic agonist properties of ephedrine--theoretical implications. Angrist, B., Rotrosen, J., Kleinberg, D., Merriam, V., Gershon, S. Psychopharmacology (Berl.) (1977)
- Effect of apomorphine, piribedil and haloperidol on adrenal ornithine decarboxylase activity of the rat. Almazan, G., Ramirez-Gonzalez, M.D., Sourkes, T.L. Neuropharmacology (1982)
- Reduced amounts of S-adenosylmethionine decarboxylase in the adrenal glands of rats following administration of piribedil or 2-deoxyglucose. Ekker, M., Sourkes, T.L., Gabor, R. Biochem. Pharmacol. (1988)
- Role of central dopaminergic mechanisms in piribedil and clonidine induced hypothermia in the rat. Reid, J.L., Lewis, P.J., Myers, M.G. Neuropharmacology (1975)
- Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. Woolverton, W.L., Goldberg, L.I., Ginos, J.Z. J. Pharmacol. Exp. Ther. (1984)
- Involvement of septal and striatal dopamine D-2 receptors in yawning behavior in rats. Yamada, K., Tanaka, M., Shibata, K., Furukawa, T. Psychopharmacology (Berl.) (1986)
- A different balance in the sensitivity of D1 and D2 dopamine receptors accounts for differences in apomorphine-induced hypothermic effects in Swiss and C3H mice. Suaudeau, C., Bousselmame, R., Costentin, J. Neuropharmacology (1992)
- Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Brocco, M., Dekeyne, A., Papp, M., Millan, M.J. Behavioural pharmacology. (2006)
- Changes of response to dopaminergic drugs in rats submitted to REM-sleep deprivation. Tufik, S. Psychopharmacology (Berl.) (1981)
- Piribedil inhibition of prolactin release induced by mechanical breast emptying in puerperal women. Alagna, S., Lodico, G., Devilla, L., Masala, A., Delitala, G., Rovasio, P.P., Stoppelli, I. Clin. Endocrinol. (Oxf) (1979)
- Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats. Mueller, G.P., Simpkins, J., Meites, J., Moore, K.E. Neuroendocrinology (1976)
- Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Nagaraja, D., Jayashree, S. The American journal of psychiatry. (2001)
- Amphetamine- type reinforcement by dopaminergic agonists in the rat. Yokel, R.A., Wise, R.A. Psychopharmacology (Berl.) (1978)
- Clinical studies with dopamine-receptor stimulants. Angrist, B., Thompson, H., Shopsin, B., Gershon, S. Psychopharmacologia. (1975)